Cristalmina® - Antiseptic - OTC

Tebarat 0.5 mg/ml eye drops are indicated for the treatment and prevention of allergic conjunctivitis. Treatment and prevention of seasonal allergic conjunctivitis symptoms in adults and children aged 4 years and over.Treatment of non-seasonal (perennial) allergic conjunctivitis symptoms in adults and chil...

Symptomatic relief of moderate to severe dry eye syndrome, using IMPACT-SVT® nanoemulsion patent drug delivery technology. 

Holistic approach for a multi-factorial pathology: anti-inflammatory, antioxidant, mucogenic, mucoadhesion, lubrication, and anti-evaporative activity. •...

Regenerate, protect against UV radiation, and lubricate. Eye tears, specially designed for after surgery.
• 20 unit dose vials of 0,4 ml • Preservative free • With Actinoquinol 0,3%, Cyanocobalamin 0,05%, PVPK 30 1,5% 

RELIVE® DRY EYE - 8 Hours of Dry Eye Relief
RELIVE® NIGHT - 12 Hours of Long-lasting Dry Eye Relief • Preservative-Free • Phosphate-Free • Single-dose vials, very Convenient format

Unique combination "ciprofloxacin 3 mg + Fluocinolone 0.25 mg" topical solution 

Indication: Acute otitis externa and acute otitis media with perforated eardrums in adults and pediatric patients. 
Dosage regimen: B.I.D x 7 days
Presentation of multi-dose 10 ml and unit dose vials (14...

Fluocinolone acetonide, topical solution. Ekzem is indicated for the treatment of otic eczema in adults. Demonstrated efficacy and safety in clinical studies 
Available in unit dose vials of 0.4 ml each. (30 vials x box)

Ciprofloxacin 3 mg, topical solution. 

Indication: AOE 
Dosage:  B.I.D x 7 days.
Presentation: Available in multidose 10ml  and unit dose vials (15 vials).

SVT-15473 is the first strongest ophthalmic corticosteroid formulated in nanoemulsion (nanodroplets below ~30nm), using IMPACT-SVT®, a patented drug delivery technology, and in single-dose vials, using Blow-Fill-Seal technology packaging.

SVT-15473 has&nbs...

Clotic® is a broad-spectrum otic antimycotic agent effective against pathogenic dermatophytes, yeasts and several species of fungus, Well-recognized safety and efficacy.
The first and only treatment with clinical evidence against otomycosis. Preservative-free.

Indication: Otic fu...

Salvat offers the best services and solutions, drawing on a long history of expertise in developing and manufacturing successful medications.

Tailored solutions to customer needs through our Ophthalmic platform: • • Customized solutions using Salvat's technology: suspensions, solutions, micellar,...

With 70 years of experience in developing and manufacturing pharmaceutical products for diverse markets, we excel in Operational Excellence, Flexibility, and Adaptability.

Salvat offers integrated CDMO services with state-of-the-art manufacturing facilities in Barcelona, Madrid, and Miami, equip...

Salvat specializes in developing and manufacturing sterile liquid pharmaceutical products in single-dose vials using Blow-Fill-Seal (BFS) technology.

Advantages of using Blow-Fill-Seal technology in your products: 
• • Innovative format, providing differentiation for your produ...

• Los ensayos clínicos fase III realizados en adultos confirman la eficacia y el excelente perfil de seguridad de SVT-15473 clobetasol oftálmico, formulado con IMPACT-SVT® tecnología patentada de nanoemulsiones, para el tratamiento de la inflamación y el dolor después de una cirugía ocular.
• Es el primer estudio clínico que se realiza en paciente pediátrico con un corticoide tópico oftálmico en toda Europa.
• Con el nuevo estudio que se inicia ahora y que se llevará a cabo en seis hospitales españoles se espera demostrar también su seguridad en pacientes pediátricos de 0 a 3 años.
• Con este proyecto, que ha supuesto una inversión global de más de 20 millones de euros, Laboratorios Salvat da un paso más en su estrategia de afianzarse como un actor clave en el área de oftalmología a nivel internacional.

Salvat has developed IMPACT-SVT®, a patented nanoemulsion drug delivery technology that improves drug mucus penetration and bio-adhesion, providing excellent ocular comfort.

IMPACT-SVT® made it possible to develop SVT-15473, using the strongest corticosteroid in the global market.

Salvat Laboratories, announced the results of phase III clinical trials of its most potent ophthalmic corticosteroid in the global ophthalmology market at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from 23-27 April 2023 in New Orleans. 

Cristalmina®, offers a quick action and long-lasting effect. 
Indicated in the disinfection of burns and superficial wounds; even for the umbilical cord in newborns.

Chlorhexidine is the antiseptic of reference, widely recommended in different clinical guidelines.

Licensing opportunity: Cristalmina®, 10 mg/ml, cutaneous spray solution in 25 ml & 125 ml.

• The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa.

• Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international level. 

 

Salvat offers an integrated End-to-Endsolution, to ensure your project’s commercial success. We offer the latest technologies withoptimum quality, flexibility andoperational excellence. With over 65years of experience, we can provide theservices and solutions that make ourpartners successful.

Salvat Laboratories, the international company, which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients.

Sharing a commitmentto patients worldwide

LICENSING-OUT our products focuson Ophthalmology, Otorhinolaryngology,Gastroenterology & Consumer Health Care.


LICENSING-IN products for the Spanish,Portuguese, African and Central Americamarkets. Our areas of interest are in Rx productsat Ophthalmology, Otorhinolaryngology andGastroenterology.

The new 8,500 m² plant is equipped with the most advanced technology, highest quality standards and the capacity to produce more than 350 million units of sterile formulations per year.

Over 60 years of experience in the pharmaceutical industry Salvat offers complete CDMO services.Expertise in Blow-Fill-Seal technology, single-dose vials
Manufacturing sites located in Barcelona, Madrid & Miami